Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
175 Leser
Artikel bewerten:
(0)

TwentyFour Income Fund - Scheme Entitlements

TwentyFour Income Fund - Scheme Entitlements

PR Newswire

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

23 March 2022

TWENTYFOUR INCOME FUND LIMITED
(a non-cellular company limited by shares incorporated in the Island of Guernsey under the Companies (Guernsey) Law 2008, as amended, with registered number 56128 and registered as a Registered Closed-ended Collective Investment Scheme with the Guernsey Financial Services Commission. LEI 549300CCEV00IH2SU369)

UK MORTGAGES LIMITED
(in voluntary winding up)
(a closed-ended investment company incorporated with limited liability under the laws of Guernsey with registered number 60440 and registered as a Registered Closed-ended Collective Investment Scheme with the Guernsey Financial Services Commission. LEI: 549300388LT7VTHCIT59)

Scheme Entitlements

Further to the announcement on 18 March 2022 in relation to the combination of TwentyFour Income Fund Limited ("TFIF") and UK Mortgages Limited (in voluntary winding up) ("UKML"), the Boards of both companies are providing the final Scheme entitlements as at the Calculation Date (18 March 2022) and as agreed in the Transfer Agreement (and as previously announced):

TFIF Issue Price per New TFIF Share£1.1421
Acquisition Value per UKML Share£0.8331
Exchange ratio (UKML:TFIF)0.72946436
Number of New TFIF Shares issued under the Scheme130,427,846

Allotments of New TFIF Shares to each UKML Shareholder on the Register on the Record Date will be rounded down to the nearest whole number of New TFIF Shares.

As noted in the Circular, UKML's joint liquidators (the "Liquidators") have appropriated to the Liquidation Pool such cash and other net current assets of UKML of a value sufficient to meet the outstanding current and future liabilities, including contingent liabilities, of UKML, all costs of UKML relating to the Proposals and the Scheme and a Retention to meet unknown and unascertained liabilities of UKML.

To the extent that any part of the Liquidation Pool is not subsequently required to discharge UKML's liabilities, it will be distributed in cash to all UKML Shareholders (in each case being those UKML Shareholders on the Effective Date in proportion to their respective holdings of UKML Shares on the Effective Date) provided that if any such amount payable to any UKML Shareholder is less than £5.00, it shall not be paid to UKML Shareholders but instead shall be paid by the Liquidators to the Nominated Charity. The Liquidators will also be entitled to make interim payments to UKML Shareholders in proportion to their holdings of UKML Shares. The Liquidators shall only make such distribution if there is sufficient cash available and if the Liquidators are of the view that it is cost effective to make an interim distribution.

UKML Shareholders should therefore keep the Registrar advised of any changes to their details after the Effective Date.

Expected timetable

2022
Date of transfer of Rollover Pool to TFIF24 March
Admission of the New TFIF Shares issued under the Scheme to the Official List and to trading on the London Stock Exchange, and dealings in the New TFIF Shares commence8.00am on 24 March
CREST accounts credited with the New TFIF Shares issued under the Scheme24 March
Share certificates in respect of the New TFIF Shares issued under the Scheme expected to be despatchedWeek commencing 28 March
UKML shares cancelled from trading on the London Stock Exchange7.30am on 30 March

Further details

Applications have been to the Financial Conduct Authority ("FCA") for admission of 130,427,846 New Ordinary Shares to the premium segment of the Official List of the FCA and to the London Stock Exchange for admission to trading on the main market for listed securities ("Admission"). It is expected that Admission will become effective at or around 8.00am on 24 March 2022 and that unconditional dealings in the New Ordinary Shares will commence at that time.

The New Ordinary Shares will, when issued, be credited as fully paid and rank pari passu with the existing Ordinary Shares in the capital of TFIF, including the right to receive all future dividends and distributions declared, made or paid.

Immediately following Admission, TFIF's issued share capital will consist of 638,942,655 Ordinary Shares with voting rights. This figure may be used by TFIF Shareholders in determining the denominator for the calculation by which they will establish if they are required to notify their interest in, or a change to their interest in TFIF under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Numis
Financial Adviser and Corporate Broker to TFIF

Hugh Jonathan / Matt Goss
Tel: 020 7260 1000

Numis
Financial Adviser and Corporate Broker to UKML

Nathan Brown / Vicki Paine
Tel: 020 7260 1000

Andrea Harris and Benjamin Rhodes of Grant Thornton
Liquidators of UKML

Tom Angus
Tel: 01534 885748

Northern Trust International Fund Administration Services (Guernsey) Limited
Company Secretary to both TFIF and UKML

Tel: 01481 745001

Notes:

Capitalised terms used in this announcement, unless otherwise defined, have the same meanings as set out in the Circular.

Numis Securities Limited ("Numis"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting for TFIF and UKML and for no one else in connection with the Scheme and will not regard any other person as its client and will not be responsible to anyone other than TFIF or UKML for providing the protections afforded to clients of Numis or for advising any such person in connection with the contents of this announcement or the Scheme.

© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.